Bristol Myers Squibb (CELG-RI) Total Debt Growth (1y) (2010 - 2026)
Bristol Myers Squibb (CELG-RI) Total Debt Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Total Debt Growth (1y) (Qtr) |
| 1 |
Gsk |
92,316,836.42 Bn |
92,316,831.46 Bn |
7.76 Bn |
8.96% |
| 2 |
Eli Lilly |
983.57 Bn |
978.29 Bn |
16.22 Bn |
12.60% |
| 3 |
Johnson & Johnson |
553.56 Bn |
531.50 Bn |
15.96 Bn |
5.23% |
| 4 |
AbbVie |
383.35 Bn |
374.00 Bn |
10.78 Bn |
-5.51% |
| 5 |
Merck |
281.71 Bn |
276.06 Bn |
12.09 Bn |
40.96% |
| 6 |
Amgen |
182.20 Bn |
170.16 Bn |
5.87 Bn |
-0.10% |
| 7 |
Gilead Sciences |
153.71 Bn |
145.98 Bn |
5.52 Bn |
-11.13% |
| 8 |
Pfizer |
143.75 Bn |
130.98 Bn |
-1.21 Bn |
3.78% |
| 9 |
Bristol Myers Squibb |
109.71 Bn |
99.25 Bn |
8.07 Bn |
-10.56% |
| 10 |
Bristol Myers Squibb |
- |
- |
8.07 Bn |
-10.56% |
| Date | Value |
|---|
| Mar 31, 2026 |
-10.56% |
| Dec 31, 2025 |
-9.14% |
| Sep 30, 2025 |
-1.56% |
| Jun 30, 2025 |
-6.12% |
| Mar 31, 2025 |
-10.72% |
| Dec 31, 2024 |
24.83% |
| Sep 30, 2024 |
32.31% |
| Jun 30, 2024 |
39.05% |
| Mar 31, 2024 |
47.18% |
| Dec 31, 2023 |
1.15% |
| Sep 30, 2023 |
-3.82% |
| Jun 30, 2023 |
-10.42% |
| Mar 31, 2023 |
-15.88% |
| Dec 31, 2022 |
-11.75% |
| Sep 30, 2022 |
-12.61% |
| Jun 30, 2022 |
-6.86% |
| Mar 31, 2022 |
-2.83% |
| Dec 31, 2021 |
-12.08% |
| Sep 30, 2021 |
-0.46% |
| Jun 30, 2021 |
-3.24% |
